Kyverna Presents Miv-cel Data Showing Sustained Mobility Improvements in Stiff Person Syndrome at One Year

PUBT · 4d ago
Kyverna Presents Miv-cel Data Showing Sustained Mobility Improvements in Stiff Person Syndrome at One Year
  • Kyverna Therapeutics plans to complete miv-cel’s rolling biologics license application for stiff person syndrome in Q4 2026, targeting a potential 2027 launch.
  • The 26-patient registrational trial met its primary endpoint, with a 46% median reduction in timed 25-foot walk at 16 weeks.
  • At one year, 92% remained off chronic SPS immunotherapies; median timed 25-foot walk improved 49% from baseline.
  • Planned pricing carries a significant premium to oncology CAR T therapies costing about $500,000-$600,000; 2,000-2,500 SPS patients are immediately addressable.
  • Phase 3 enrollment in generalized myasthenia gravis is expected to finish by mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.